New hope for ovarian cancer: study tests powerful drug combo before surgery
NCT ID NCT05446870
Summary
This study tested whether adding an experimental drug called MK-4830 to standard immunotherapy and chemotherapy could better shrink tumors before surgery in people with high-grade ovarian cancer. Researchers measured tumor DNA in the blood to see if the new combination was more effective at reducing cancer levels. The trial involved 160 participants who had not received prior treatment for their ovarian cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ Maria Middelares-IKG ( Site 1302)
Ghent, Oost-Vlaanderen, 9000, Belgium
-
Antwerp University Hospital-Oncology ( Site 1301)
Edegem, Antwerpen, 2650, Belgium
-
Centre Hospitalier de l'Université de Montréal ( Site 0300)
Montreal, Quebec, H2X 3E4, Canada
-
Changhua Christian Hospital-Obstetrics and Gynecology ( Site 1203)
Changhua County, Changhua, 50006, Taiwan
-
FALP ( Site 0905)
Santiago, Region M. de Santiago, 7500921, Chile
-
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Chirurgia Ginecologica ( Site 050
Milan, Lombardy, 20133, Italy
-
Fondazione Policlinico Universitario Agostino Gemelli-Ginecologia Oncologica ( Site 0502)
Rome, Lazio, oo168, Italy
-
Fred Hutchinson Cancer Center ( Site 0100)
Seattle, Washington, 98109, United States
-
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1101)
Barcelona, 08035, Spain
-
Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1104)
Madrid, Madrid, Comunidad de, 28041, Spain
-
Instituto Catalan de Oncologia - Hospital Duran i Reynals-Medical Oncology ( Site 1103)
Hospitalet, Barcelona, 08907, Spain
-
Istituto Europeo di Oncologia IRCCS-Divisione di Ginecologia Oncologica ( Site 0501)
Milan, 20141, Italy
-
Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Oncologia Sperimentale Uro-Genitale ( Site 0
Naples, Campania, 80131, Italy
-
James Lind Centro de Investigación del Cáncer ( Site 0903)
Temuco, Región de la Araucanía, 4800827, Chile
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0107)
New York, New York, 10016, United States
-
Mackay Memorial Hospital ( Site 1204)
Taipei, 10449, Taiwan
-
Mayo Clinic in Florida ( Site 0101)
Jacksonville, Florida, 32224, United States
-
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 0701)
Siedlce, Masovian Voivodeship, 08-110, Poland
-
McGill University Health Centre ( Site 0301)
Montreal, Quebec, H4A 3J1, Canada
-
Memorial Sloan Kettering Cancer Center ( Site 0102)
New York, New York, 10065, United States
-
Miami Cancer Institute at Baptist Health, Inc. ( Site 0110)
Miami, Florida, 33176, United States
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Ginekologii Onkologicznej ( Sit
Warsaw, Masovian Voivodeship, 02-781, Poland
-
National Cancer Centre Singapore ( Site 1501)
Singapore, Central Singapore, 168583, Singapore
-
National Cheng Kung University Hospital ( Site 1201)
Tainan, 704, Taiwan
-
National Taiwan University Hospital-Internal Medicine ( Site 1200)
Taipei, 10002, Taiwan
-
National University Hospital ( Site 1502)
Singapore, South West, 119074, Singapore
-
Northwestern Memorial Hospital ( Site 0104)
Chicago, Illinois, 60611, United States
-
ONCOCENTRO APYS-ACEREY ( Site 0904)
Viña del Mar, Región de Valparaíso, 2520598, Chile
-
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0116)
Mineola, New York, 11501, United States
-
Pontificia Universidad Catolica de Chile-Centro del Cáncer ( Site 0900)
Santiago, Region M. de Santiago, 8330032, Chile
-
Rambam Health Care Campus-Gyneco-oncology unit ( Site 0602)
Haifa, 3109601, Israel
-
Roswell Park Cancer Institute ( Site 0106)
Buffalo, New York, 14263, United States
-
Rutgers Cancer Institute of New Jersey ( Site 0114)
New Brunswick, New Jersey, 08901, United States
-
Sanford Cancer Center-Gynecologic Oncology ( Site 0115)
Sioux Falls, South Dakota, 57104, United States
-
Seoul National University Hospital ( Site 0801)
Seoul, 03080, South Korea
-
Severance Hospital, Yonsei University Health System-Gynecologic cancer center ( Site 0800)
Seoul, 03722, South Korea
-
Shaare Zedek Medical Center ( Site 0601)
Jerusalem, 9103102, Israel
-
Sheba Medical Center-ONCOLOGY ( Site 0600)
Ramat Gan, 5265601, Israel
-
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 0708)
Kielce, Świętokrzyskie Voivodeship, 25-734, Poland
-
Taichung Veterans General Hospital-GYNECOLOGY ( Site 1202)
Taichung, 407, Taiwan
-
UZ Leuven ( Site 1300)
Leuven, Vlaams-Brabant, 3000, Belgium
-
University of Colorado Anschutz Medical Campus-Cancer Clinical Trials Office ( Site 0108)
Aurora, Colorado, 80045, United States
-
Uniwersytecki Szpital Kliniczny w Poznaniu-Oddzial Ginekologii Onkologicznej ( Site 0709)
Poznan, Greater Poland Voivodeship, 61-848, Poland
-
Uniwersyteckie Centrum Kliniczne-Klinika Ginekologii, Ginekologii Onkologicznej i Endokrynologii Gi
Gdansk, Pomeranian Voivodeship, 80-214, Poland
-
Washington University ( Site 0113)
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.